Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial
2024 · European Journal of Cancer · 1 citations
https://doi.org/10.1016/j.ejca.2024.115108